<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558723</url>
  </required_header>
  <id_info>
    <org_study_id>20-275</org_study_id>
    <secondary_id>CMR-ICD-DZHK23</secondary_id>
    <nct_id>NCT04558723</nct_id>
  </id_info>
  <brief_title>C-MRI Guidance of Implantable CRT-implantation in Non-ischemic Dilated Cardiomyopathy</brief_title>
  <acronym>CMR-ICD</acronym>
  <official_title>Randomized Controlled, Multi-centre Trial of Cardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Ingo Eitel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with diagnostic CMR images for assessment of LGE/fibrosis and evidence/presence of&#xD;
      non-ischaemic myocardial fibrosis/scar will be randomized to the following treatment groups&#xD;
      in a 1:1 ratio: ICD group or Optimal HF care group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the hypothesis that implantable&#xD;
      cardioverter defibrillator (ICD) therapy would decrease the risk of death from any cause in&#xD;
      comparison to optimal heart failure (HF) care without ICD insertion in patients with NIDCM,&#xD;
      left ventricular ejection fraction (LVEF) ≤35% and presence of myocardial fibrosis on cardiac&#xD;
      magnetic resonance (CMR) imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>Day 0</time_frame>
    <description>Death from any causes during follow-up - after discharge.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">760</enrollment>
  <condition>Non-ischemic Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>ICD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving OMT and ICD or cardiac resynchronization therapy with a defibrillator (CRT-D) if indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal HF care group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receiving OMT and CRT pacemaker (CRT-P) implantation without a defibrillator if indicated. Patients without CRT indication will receive an ICM for detection of malignant VAs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ICD/CRT-D implantation</intervention_name>
    <description>ICD/CRT-D implantation (if indicated)</description>
    <arm_group_label>ICD group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NIDCM (idiopathic or familial)*&#xD;
&#xD;
          -  LVEF ≤35% and presence of fibrosis on CMR&#xD;
&#xD;
          -  Diagnostic CMR scan&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ICM [previous myocardial infarction, previous percutaneous coronary intervention]&#xD;
&#xD;
          -  Other cardiomyopathies (hypertrophic cardiomyopathy, arrhythmogenic right ventricular&#xD;
             cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathies [e.g.&#xD;
             cardiac amyloidosis, cardiac sarcoidosis, hemochromatosis and iron overload&#xD;
             cardiomyopathy], left ventricular non-compaction cardiomyopathy, reversible&#xD;
             cardiomyopathies [Takotsubo syndrrome, peripartum cardiomyopathy, chemotherapy induced&#xD;
             cardiomyopathy].&#xD;
&#xD;
          -  Myocarditis&#xD;
&#xD;
          -  Contraindication for CMR at study entry (including severe claustrophobia, pacemaker or&#xD;
             ICD, metallic cerebral or intracranial implants, known allergy to gadolinium)&#xD;
&#xD;
          -  Severe renal insufficiency (creatinine clearance &lt;30 mL/min)&#xD;
&#xD;
          -  Current pacemaker or defibrillator in situ&#xD;
&#xD;
          -  Current indication for device therapy (e.g. secondary prophylaxis after aborted SCD)&#xD;
&#xD;
          -  Renal impairment defined as an eGFR &lt;30 milliliters&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Patients presenting with pregnancy&#xD;
&#xD;
          -  Patients without informed consent&#xD;
&#xD;
          -  Participation in another randomized trial&#xD;
&#xD;
          -  Life expectancy &lt;2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingo Eitel, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Clinic II - University Heart Center Lübeck</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingo Eitel, Prof. Dr.</last_name>
    <phone>+49 451 500 44501</phone>
    <email>ingo.eitel@uksh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Stiermaier, Dr.</last_name>
    <phone>+49 451 500 44501</phone>
    <email>thomas.stiermaier@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universität zu Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingo Eitel, Prof. Dr. med.</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas Stiermaier, Dr.med</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Ingo Eitel</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

